Daprodustat - Latest Advances

Structure-Based Optimization of HIF-2α Agonists That Synergistically Enhance Erythropoietin Production with PHD Inhibitors.

Journal: Journal of medicinal chemistry

Published: October 06, 2025

Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan.

Journal: Current medical research and opinion

Published: September 19, 2025

In Vitro and Ex Vivo Evidences that Pharmacological Induction of the Hypoxia Response Pathway Efficiently Restricts Measles and Nipah Virus Infections.

Journal: Emerging microbes & infections

Published: September 17, 2025

Effects of Daprodustat on Iron Metabolism in Peritoneal Dialysis Patients: An Exploratory Study.

Journal: Blood purification

Published: August 11, 2025

The Safety and Efficacy of Daprodustat for Recipients in Peritransplant Period: a Single-Center Retrospective Study on Post-Transplant Anemia Management in Kidney Transplantation.

Journal: Transplant international : official journal of the European Society for Organ Transplantation

Published: July 08, 2025

Daprodustat for patients with heart failure and renal anemia: A pilot multicenter, open-label, randomized controlled study.

Journal: Journal of cardiology

Published: June 21, 2025

Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology.

Journal: Expert opinion on drug safety

Published: March 06, 2025

Daprodustat: a new approach to the treatment of anemia in chronic kidney disease.

Journal: Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti

Published: March 04, 2025

Vadadustat (Vafseo) for anemia of chronic kidney disease.

Journal: The Medical letter on drugs and therapeutics

Published: February 13, 2025

Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 07, 2024

Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials.

Journal: Journal of pharmacological sciences

Published: October 16, 2024

The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review.

Journal: Frontiers in nephrology

Published: October 15, 2024

Filters

Structure-Based Optimization of HIF-2α Agonists That Synergistically Enhance Erythropoietin Production with PHD Inhibitors.

Structure-Based Optimization of HIF-2α Agonists That Synergistically Enhance Erythropoietin Production with PHD Inhibitors.

Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan.

Characteristics and management of patients with renal anaemia treated with daprodustat: an observational study in Japan.

In Vitro and Ex Vivo Evidences that Pharmacological Induction of the Hypoxia Response Pathway Efficiently Restricts Measles and Nipah Virus Infections.

In Vitro and Ex Vivo Evidences that Pharmacological Induction of the Hypoxia Response Pathway Efficiently Restricts Measles and Nipah Virus Infections.

Effects of Daprodustat on Iron Metabolism in Peritoneal Dialysis Patients: An Exploratory Study.

Effects of Daprodustat on Iron Metabolism in Peritoneal Dialysis Patients: An Exploratory Study.

The Safety and Efficacy of Daprodustat for Recipients in Peritransplant Period: a Single-Center Retrospective Study on Post-Transplant Anemia Management in Kidney Transplantation.

The Safety and Efficacy of Daprodustat for Recipients in Peritransplant Period: a Single-Center Retrospective Study on Post-Transplant Anemia Management in Kidney Transplantation.

Daprodustat for patients with heart failure and renal anemia: A pilot multicenter, open-label, randomized controlled study.

Daprodustat for patients with heart failure and renal anemia: A pilot multicenter, open-label, randomized controlled study.

Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology.

Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology.

Daprodustat: a new approach to the treatment of anemia in chronic kidney disease.

Daprodustat: a new approach to the treatment of anemia in chronic kidney disease.

Vadadustat (Vafseo) for anemia of chronic kidney disease.

Vadadustat (Vafseo) for anemia of chronic kidney disease.

Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease.

Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease.

Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials.

Efficacy and safety of daprodustat versus darbepoetin alfa in the treatment of anemia in chronic renal failure: Systematic review and meta-analysis of randomized controlled trials.

The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review.

The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review.